Skip to main content
main-content

10.06.2017 | Original Article | Ausgabe 2/2018

Indian Journal of Thoracic and Cardiovascular Surgery 2/2018

Diagnostic and prognostic efficacy of Von Willebrand factor and Clara cell in traumatic lung injury

Zeitschrift:
Indian Journal of Thoracic and Cardiovascular Surgery > Ausgabe 2/2018
Autoren:
Suresh Kumar, Anand Pandey, Sanjeev Kumar, Sumit Pratap Singh, Arshad Ahmad, Mohammad Kaleem Ahmad

Abstract

Background

Chest injury is one of the most frequent causes of death and complications in different societies. The search for a marker of lung injury is desirable for diagnosis and prognosis. This study was conducted to assess the serum level of Von Willebrand factor (VWF) and Clara cell secretory protein (CC16) as biomarker in traumatic lung injuries for diagnostic and prognostic significance.

Methods

We evaluated the demographic data of all patients of chest injury presenting to the department. Mode of injury, any intervention, and outcome were evaluated. The level of the VWF and CC16 was assessed as per protocol.

Results

The duration of this study was 1 year. The total number of patients was 96. The mean age of patients was 40.84 ± 9.89 (range 14–70 years). Male to female ratio was 5.4:1. There was a statistically significant association of VWF with diagnosis of patient. Markedly elevated levels of VWF were associated with high mortality rates (p = 0.002). The level of VWF was markedly raised in patient having duration of hospital stay more than 2 weeks (p = 0.001). There was a statistically significant association of CC16 with diagnosis of patient. Markedly elevated level of CC16 was associated with high mortality rates (p = 0.001). The level of CCI6 was markedly raised in patients having duration of hospital stay more than 2 weeks (p = 0.001).

Conclusion

VWF and CC16 appear to be useful markers for thoracic trauma. They may also be helpful for the prognosis of the patient. Further studies evaluating their role may substantiate our efforts.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

Indian Journal of Thoracic and Cardiovascular Surgery 2/2018 Zur Ausgabe
  1. Sie können e.Med Chirurgie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise